Not applicable
ID
Bron
Verkorte titel
Aandoening
Portal vein obstruction
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Primary and secondary patency after PVO intervention, and patient and graft survival after PVO intervention
Achtergrond van het onderzoek
Therapeutic strategies to treat portal vein obstruction (PVO) include percutaneous transluminal angioplasty (PTA) with or without stent, Mesorex Bypass (MRB)/other surgical shunts, endovascular recanalization, endovascular splenic arterial embolisation, splenectomy, and conservative treatment. PTA is the treatment option where the most publications refer to. However, currently only small single centre studies are reported and frequently with different treatment protocols. The primary objective of this study is to assess the efficacy of the individual treatments for PVO after paediatric liver transplantation and determine patient and graft survival. Secondary objectives are to asses prevalence numbers of PVO, technical success, post-treatment complications and medicinal management
Doel van het onderzoek
Not applicable
Onderzoeksopzet
Intervention between January 2001 and January 2021 will be retrospectively analyzed
Onderzoeksproduct en/of interventie
No interventions; this is a retrospective, observational registry
Algemeen / deelnemers
Wetenschappers
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Treated for PVO (PVAS or PVT) after liver transplantation (all interventions are included and conservative treatment as well)
2. Age at intervention <18 years
3. Intervention in period 01-01-2001 and 01-01-2021
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
None
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL9261 |
| Ander register | METC UMCG : METc 2021/072 |